The role of autoantibodies in Alzheimer's disease: Pathogenetic connections or epiphenomena?

TL;DR

This paper reviews the role of autoantibodies in Alzheimer's disease, suggesting many findings may be false and emphasizing the need for validation.

Contribution

The paper highlights the potential for false discoveries in autoantibody research for Alzheimer's and advocates for rigorous validation methods.

Findings

Autoantibodies like those against amyloid β and tau are reported in Alzheimer's but lack consistent replication.

Many autoantibody findings in Alzheimer's may be false discoveries requiring orthogonal validation.

Understanding immune dysregulation could lead to new diagnostic and therapeutic strategies for Alzheimer's.

Abstract

The current evidence supporting the complex, multifaceted etiology for Alzheimer's disease (AD) grows by the day, prompting increased research in non‐“amyloid hypothesis”‐related pathways. One of these pathways of interest pertains to an autoimmune component in this disease.

In this review, we briefly discuss current evidence of potential contributions of autoimmunity to AD pathobiology and describe the putative role of autoantibodies detected in patient fluids. We draw attention to the fact that the reported AD‐related autoantibodies differ dramatically between published studies, raising doubts about the reliability and robustness of these findings.

We hypothesize, and provide indirect evidence, that many of the reported autoantibodies in AD may represent false discoveries. We suggest follow‐up validation and confirmatory studies with sufficient power, preferably by employing orthogonal testing techniques.

Uncovering the putative autoimmune components of AD is important and could pave the way to new concepts for AD pathogenesis, diagnosis, and therapy.

Although Alzheimer's disease (AD) is not traditionally considered an autoimmune disease, growing evidence suggests immune system dysregulation and autoantibody generation, either in the form of naturally occurring or pathogenic autoantibodies.Numerous studies have discovered autoantibodies in AD, but only a few of them have been found independently and multiple times, including amyloid β (Aβ) and tau autoantibodies.Many of these findings represent false discoveries.Follow‐up validation and confirmatory studies with sufficient power are imperative, preferably by employing orthogonal testing techniques.Understanding the immune and autoimmune landscape in AD will assist in future immunotherapy strategies.

Although Alzheimer's disease (AD) is not traditionally considered an autoimmune disease, growing evidence suggests immune system dysregulation and autoantibody generation, either in the form of naturally occurring or pathogenic autoantibodies.

Numerous studies have discovered autoantibodies in AD, but only a few of them have been found independently and multiple times, including amyloid β (Aβ) and tau autoantibodies.

Many of these findings represent false discoveries.

Follow‐up validation and confirmatory studies with sufficient power are imperative, preferably by employing orthogonal testing techniques.

Understanding the immune and autoimmune landscape in AD will assist in future immunotherapy strategies.

Figures